ReviewArchives of endocrinology and metabolism2023
Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions.
Review in Archives of endocrinology and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- Obesity and Cancer: From Systemic Metabolic Reprogramming to Immunotherapy Paradox.Metabolites · 2026Review
- Rising trends in obesity and cancer-related mortality in the United States: a population-based analysis, 1999-2020.Journal of the Endocrine Society · 2026Article
- GCGR agonism requires GABAergic signaling in the medial basal hypothalamus to promote weight loss in obese mice.Molecular metabolism · 2026Article
- Mid-Term Changes in Quality of Life and Nutritional Habits Following Gastric Bypass: A 24-Month Follow-Up Study.Nutrients · 2026Article
- Female cancers in adolescent and young adult women: global inequities and 2050 burden estimates from GLOBOCAN 2022.Frontiers in oncology · 2026Article
- Dysregulation of adipokines in the serum of breast cancer patients - role in pathogenesis and potential clinical application (preliminary studies).Frontiers in immunology · 2026Article
- The Role of "Metabolic Instability" as a New Risk Criterion in the Pathogenesis of Endometrial Cancer.Cancers · 2025Review
- Effects of tailored exercise on glycemic and nutritional outcomes in diabetic patients with colorectal cancer and on chemotherapy.World journal of diabetes · 2025Article
- Obesity as a Multifactorial Chronic Disease: Molecular Mechanisms, Systemic Impact, and Emerging Digital Interventions.Current issues in molecular biology · 2025Review
- Association of diabetes mellitus and breast cancer in adult men and women: a cross-sectional survey.BMC cancer · 2025Article
- Hyperglycemia and Obesity as the Key Drivers of Increased Colorectal Cancer Mortality in the North Africa and Middle East Region.Oman medical journal · 2025Article
- Global regional, and national burden of type 2 diabetes attributable to dietary factors from 1990 to 2021.Scientific reports · 2025Article
- Behavioral risk factors in oncology patients: A matched case control study from Yemen.PloS one · 2025Article
- Inflammation-driven mechanisms in endometrial cancer: pathways from inflammatory microenvironment remodeling to immune escape.Frontiers in immunology · 2025Review
- Obesity indices and their sociodemographic, lifestyle, and social isolation correlates in a large Spanish working population.Frontiers in endocrinology · 2025Article
- Therapeutic Potential of Dimethyl Fumarate for the Treatment of High-Fat/High-Sucrose Diet-Induced Obesity.Antioxidants (Basel, Switzerland) · 2024Article
- The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights.Diagnostics (Basel, Switzerland) · 2024Review
- How do gamified digital therapeutics work on obesity self-management?Metabolism open · 2024Review
- What will we see in diabetes in the next 10 years?Journal of diabetes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proportion of deaths attributable to cancer is rising, and malignant neoplasms have become the leading cause of death in high-income countries. Obesity and diabetes are now recognized as risk factors for several types of malignancies, especially endometrial, colorectal, and postmenopausal breast cancers. Mechanisms implicated include disturbances in lipid-derived hormone secretion, sex steroids biosynthesis, hyperinsulinemia, and chronic inflammation. Intentional weight loss is associated with a mitigation of risk for obesity-related cancers, a phenomenon observed specially with bariatric surgery. The impact of pharmacological interventions for obesity and diabetes is not uniform: while metformin seems to protect against cancer, other agents such as lorcaserin may increase the risk of malignancies. However, these interpretations must be carefully considered, since most data stem from bias-prone observational studies, and high-quality randomized controlled trials with appropriate sample size and duration are needed to achieve definite conclusions. In this review, we outline epidemiological and pathophysiological aspects of the relationship between obesity, diabetes, and malignancies. We also highlight pieces of evidence regarding treatment effects on cancer incidence in these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.